Search Results for “ diabetes” – Page 9 – media

Cancer cells killed off with diabetes drug

Scientists may have found an innovative way to kill off cancer cells in acute myeloid leukemia(AML), all the while preserving and regenerating healthy red blood cells.
- Source: medicalnewstoday
- 756
- October 24, 2017
AML anemia cancer leukemia Researches
Blood sugar pill shows promise

The pill form of the drug semaglutide is worth pursuing as a way to control blood sugar in patients with type 2 diabetes, say researchers.
- Source: medicalnewstoday
- 587
- October 18, 2017
diabetes glycemic Phase Researches semaglutide
FDA rejects Intarcia’s hotly promoted diabetes drug/device, citing manufacturing issues

Boston-based Intarcia Therapeutics became the latest casualty of the FDA’s manufacturing standards. The agency has rejected Intarcia’s implanted diabetes drug/device, which company execs have long insisted is on a straight path to blockbuster sales.
- Source: Endpts
- 426
- September 29, 2017
Company Insight diabetes implanted
Nemaura develops medical grade diabetes management app

Nemaura Medical Inc. (NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system announced today that it has completed development of a medical grade app prepared and verified in accordance with ISO13485 quality systems and the appropriate medical devices directives, and designed to be used with the sugarBEAT® device or with glucose meters and strips to display glucose levels on users android mobile devices.
- Source: Drugdeliverybusiness
- 664
- September 1, 2017
diabetes glucose Nemaura Medical Researches
Diabetes prescriptions rocket 80 percent in a decade

Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.
- Source: pharmatimes
- 556
- August 3, 2017
diabetes Market Views Researches
Tentative US approval for Merck’s diabetes therapy

The US Food and Drug Administration has given a tentative green light to Merck & Co’s follow-on biologic basal insulin Lusduna Nexvue.
- Source: pharmatimes
- 474
- July 21, 2017
Company Insight diabetes Lusduna Nexvue Market Views
As the industry is going down, more and more pharmaceutical companies are seeking to “exit”?

In February this year, China Resources Double Crane acquired 100% of the equity of China Resources Zizhu for 3.1 billion yuan, enriched Double Crane’s specialty product line through Zizhu’s core products such as Yuting and Jin Yuting, formed a “women’s health + pediatrics” specialty product sequence, and improved the product matrix; in March, Xintian Pharmaceutical, which mainly engages in traditional Chinese medicine business, announced that it plans to acquire 85.12% of Huilun Pharmaceutical’s equity through issuing shares, expanding its business to the field of small molecule chemical drugs; in June, the domestic contrast agent leader Beilu Pharmaceutical acquired Chengde Tianyuan Pharmaceutical for 202 million yuan. 80% equity, expanding its coverage in the field of traditional Chinese medicine; in October, the plan for SinoVac (Shijiazhuang Pharmaceutical Innovation) to acquire Shijiazhuang Baike was released. SinoVac will acquire 100% equity of Shijiazhuang Baike for a total price of up to 7.6 billion yuan ...
- Source: drugdu
- 24
- November 22, 2024
Novo Nordisk’s weekly weight loss formulation is officially launched

On November 17, Novo Nordisk announced that its weekly formulation of glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide (trade name: Novowin) for long-term weight management was officially launched in China, providing a weight loss option for Chinese overweight and obese patients. It is understood that with the official commercialization of Novowin, the first prescription of semaglutide for weight loss indications in public hospitals will be issued in Shanghai next week. Regarding the pricing of Novowin, Novo Nordisk responded: “We have begun to apply for Novowin provincial bidding network, and the sales price will refer to the provincial online price.” Previously, Novo Nordisk’s semaglutide for the treatment of type 2 diabetes, Novotai, has been included in the medical insurance, and the cost of a 3 ml dose is less than 800 yuan. In addition, Novowin has previously entered the private hospital channel and can be booked through the Internet platform, with a ...
- Source: drugdu
- 33
- November 21, 2024
Four innovative pharmaceutical companies have completed a new round of financing! 3 from China

According to the Instant Drug Database, last week (November 4th to November 10th), at least four emerging companies dedicated to innovative drug research and development worldwide announced the completion of a new round of financing, including three Chinese companies. These emerging companies that have gained favor in the capital market are developing drug types such as gene therapy drugs, iPSC cell therapy drugs, peptide vaccines, and antibody conjugated drugs (ADCs) with dual payloads. Kanglin Biotechnology Financing round: Series A Financing amount: 150 million yuan On November 8th, Kanglin Biotechnology (Hangzhou) Co., Ltd. (referred to as “Kanglin Biotechnology”) announced the completion of a 150 million yuan Series A financing, jointly invested by Zhejiang Province’s “4+1” Biomedical and High end Device Industry Fund and old shareholder Zhejiang Miyin Investment Management Co., Ltd. Kanglin Biology was founded in 2015, focusing on the R&D and commercialization of innovative drugs for gene therapy, targeting diseases ...
- Source: drugdu
- 52
- November 13, 2024
The National Medical Insurance Bureau notified that the prices of many types of inspection items have been reduced.

Recently, the National Medical Insurance Bureau has uniformly deployed various provinces to carry out standardized governance of medical service prices, promote reasonable price reductions for some large-volume and high-priced inspection and testing items, further reduce the burden on patients to see doctors, and promote the relative balance of inspection and testing prices among provinces. Which items will be focused on? At present, there are more than 2,000 inspection and testing items in various provinces across the country. Affected by factors such as information barriers, the prices of some items vary greatly in different provinces. For example, the thromboelastogram test, which is a test used to evaluate coagulation function, costs 360 yuan per time in some places and only 100 yuan per time in some places, which is several times different. The reason behind this is mainly that the procurement costs of some inspection reagents or equipment are inflated, resulting in ...
- Source: drugdu
- 44
- November 12, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.